What does “Jardiance” LOE mean?
“LOE” usually means “loss of exclusivity,” the point when a brand drug’s market protection starts to weaken enough for generic or (for biologics) biosimilar competition to enter. That timing can be driven by patent expirations, regulatory exclusivity, and court rulings.
When is Jardiance’s loss of exclusivity (LOE)?
To answer “Jardiance LOE” with dates, I need the specific country/market you mean (for example, US/EMA vs. a particular launch year), because LOE timing differs by jurisdiction and by whether you’re asking about branded tablets vs. specific strengths/formulations.
If you mean the US, you can check the latest patent/LOE breakdown here on DrugPatentWatch: https://www.drugpatentwatch.com/ (search for “Jardiance”).
Is Jardiance’s LOE tied to generic entry?
Often yes. Once LOE hits, generic companies may be able to launch if they also have appropriate FDA approvals (and no stay/other litigation blocks the launch). The exact launch timing can still shift due to patent litigation or regulatory events.
Which product are you asking about?
Jardiance is the brand name for empagliflozin. Different strengths and line extensions can have different protection timelines. Tell me:
- “US” or another country/region
- whether you mean tablets in general or a specific strength (e.g., 10 mg, 25 mg)
and I’ll narrow it to the relevant LOE timing.
Sources
- [1] https://www.drugpatentwatch.com/